Literature DB >> 6193853

Comparative study of the beta-lactamase activity found in Achromobacter.

R Levesque, R Letarte, J C Pechère.   

Abstract

A survey of 21 clinical isolates of Achromobacter species demonstrated a high level of beta-lactamase activity in all strains tested. The beta-lactamases were characterized by isoelectric focusing, purification by affinity chromatography, determination of molecular weight, immunological identity, and genetic analysis. At least three distinct patterns of beta-lactamases were found in 19 strains. The kinetic values Km and Vmax measured by a microacidimetric method showed that all three types of enzymes are cephalosporinases and did not hydrolyse oxacillin, cloxacillin, and methicillin. Two of the three types of cephalosporinases studied, namely MULB 901 (isoelectric point (pI)7.4) and MULB 905(pI 9.3) are enzymes mediated by genes of chromosomal origin. The MULB 906 (pI 8.1) enzyme, however, which has been previously shown to be mediated by an 8.2 MDal nonconjugative plasmid, showed hydrolysis of cefoxitime, cefotaxin, and moxalactam by the bioassay. In all cases, beta-lactamase synthesis appeared constitutive. This study confirms that beta-lactamase activity is commonly found in Achromobacter and that these enzymes are different and of clinical interest when compared with those observed in other Gram-negative bacteria.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6193853     DOI: 10.1139/m83-133

Source DB:  PubMed          Journal:  Can J Microbiol        ISSN: 0008-4166            Impact factor:   2.419


  10 in total

Review 1.  Beta-lactamase nomenclature.

Authors:  George A Jacoby
Journal:  Antimicrob Agents Chemother       Date:  2006-04       Impact factor: 5.191

2.  Identification of an inducible penicillinase of the lithoautotrophic hydrogen-oxidizing bacterium Alcaligenes eutrophus.

Authors:  P Sebo; J Stastná
Journal:  Folia Microbiol (Praha)       Date:  1987       Impact factor: 2.099

3.  Cloning and expression of the imipenem-hydrolyzing beta-lactamase operon from Pseudomonas maltophilia in Escherichia coli.

Authors:  J Dufresne; G Vézina; R C Levesque
Journal:  Antimicrob Agents Chemother       Date:  1988-06       Impact factor: 5.191

4.  Susceptibility of Alcaligenes denitrificans subspecies xylosoxydans to beta-lactam antibiotics.

Authors:  K Mensah; A Philippon; C Richard; P Névot
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-06       Impact factor: 3.267

5.  Genomic insights into intrinsic and acquired drug resistance mechanisms in Achromobacter xylosoxidans.

Authors:  Yongfei Hu; Yuying Zhu; Yanan Ma; Fei Liu; Na Lu; Xi Yang; Chunguang Luan; Yong Yi; Baoli Zhu
Journal:  Antimicrob Agents Chemother       Date:  2014-12-08       Impact factor: 5.191

6.  Characterization of a naturally occurring class D beta-lactamase from Achromobacter xylosoxidans.

Authors:  Yohei Doi; Laurent Poirel; David L Paterson; Patrice Nordmann
Journal:  Antimicrob Agents Chemother       Date:  2008-03-24       Impact factor: 5.191

7.  Peritonitis caused by Alcaligenes denitrificans subsp. xylosoxydans: case report and review of the literature.

Authors:  A J Morrison; K Boyce
Journal:  J Clin Microbiol       Date:  1986-11       Impact factor: 5.948

8.  Genomic Insights into Achromobacter mucicolens IA Antibiotic Resistance.

Authors:  Sura Ali Al-Asadi; Rusul Emaduldeen S Al-Kahachi; Wifaq M Ali Alwattar; Jamila Bootwala; Majeed Arsheed Sabbah
Journal:  Microbiol Spectr       Date:  2022-04-04

9.  First genome sequences of Achromobacter phages reveal new members of the N4 family.

Authors:  Johannes Wittmann; Brigitte Dreiseikelmann; Manfred Rohde; Jan P Meier-Kolthoff; Boyke Bunk; Christine Rohde
Journal:  Virol J       Date:  2014-01-27       Impact factor: 4.099

10.  Isolation and characterization of numerous novel phages targeting diverse strains of the ubiquitous and opportunistic pathogen Achromobacter xylosoxidans.

Authors:  Johannes Wittmann; Brigitte Dreiseikelmann; Christine Rohde; Manfred Rohde; Johannes Sikorski
Journal:  PLoS One       Date:  2014-01-22       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.